William G Herrington
Overview
Explore the profile of William G Herrington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madero M, Levin A, Ahmed S, Carrero J, Foster B, Francis A, et al.
Ann Intern Med
. 2025 Mar;
PMID: 40063957
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease...
2.
Zhu D, Judge P, Wanner C, Haynes R, Herrington W
Kidney Int
. 2025 Feb;
PMID: 39986466
Treatment of patients with chronic kidney disease (CKD) requires implementation of prevention and management strategies that reduce the risk of kidney failure and CKD-associated cardiovascular risk. Metabolic syndrome is characterized...
3.
Zhu D, Judge P, Staplin N, Haynes R, Herrington W
Nephrol Dial Transplant
. 2025 Feb;
40(Supplement_1):i70-i79.
PMID: 39907541
Abstract: Nephrology has benefited from conducting increasingly large high-quality trials in the last 5-10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple...
4.
Judge P, Tuttle K, Staplin N, Hauske S, Zhu D, Sardell R, et al.
Nephrol Dial Transplant
. 2024 Nov;
PMID: 39533115
Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium...
5.
Zhu D, Herrington W
Ann Intern Med
. 2024 Nov;
177(11):JC122.
PMID: 39496170
Lingvay I, Deanfield J, Kahn SE, et al; SELECT Trial Investigators. Diabetes Care. 2024;47:1360-1369. 38907684.
6.
Zhu D, Herrington W
Ann Intern Med
. 2024 Nov;
177(11):JC123.
PMID: 39496169
Usman MS, Bhatt DL, Hameed I, et al. Lancet Diabetes Endocrinol. 2024;12:447-461. 38768620.
7.
Trichia E, Alegre-Diaz J, Aguilar-Ramirez D, Ramirez-Reyes R, Garcilazo-Avila A, Gonzalez-Carballo C, et al.
Lancet Public Health
. 2024 Nov;
9(11):e907-e915.
PMID: 39486906
Background: Alcohol consumption is a leading cause of premature death globally, but there is no large-scale prospective evidence from Mexico. Methods: The Mexico City Prospective Study recruited 150 000 adults...
8.
Herrington W, Staplin N, Agrawal N, Wanner C, Green J, Hauske S, et al.
N Engl J Med
. 2024 Oct;
392(8):777-787.
PMID: 39453837
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial...
9.
Mayne K, Sardell R, Staplin N, Judge P, Zhu D, Sammons E, et al.
Nephrol Dial Transplant
. 2024 Sep;
PMID: 39277784
Background And Hypothesis: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout...
10.
Apperloo E, Neuen B, Fletcher R, Jongs N, Anker S, Bhatt D, et al.
Lancet Diabetes Endocrinol
. 2024 Jul;
12(8):545-557.
PMID: 38991584
Background: SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are...